<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008215</url>
  </required_header>
  <id_info>
    <org_study_id>09-282</org_study_id>
    <nct_id>NCT01008215</nct_id>
  </id_info>
  <brief_title>Simple Warfarin Dosing Algorithm Study</brief_title>
  <acronym>KT-INR</acronym>
  <official_title>Cluster Randomized Trial to Assess the Effect of Using a Simple Warfarin Maintenance Dosing Algorithm on the Quality of INR Control Among Canadian Family Practices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can a simple and cost-free tool help family physicians to improve dosing of the blood thinner&#xD;
      warfarin?&#xD;
&#xD;
      Warfarin is a blood thinner with a variable effect and requires regular blood monitoring and&#xD;
      dose adjustments. Some family practices do not have the facilities or funding to use&#xD;
      commercial tools than can assist with stabilizing the effect of warfarin. The investigators&#xD;
      will test whether a simple and cost-free dosing tool can help these practices to improve&#xD;
      warfarin management.&#xD;
&#xD;
      If this simple tool improves warfarin management, it will be freely available for practices&#xD;
      in Canada and around the world. This will help physicians who have no access to more costly&#xD;
      and/or complicated tools improve their warfarin dosing practice in a systematic fashion, and&#xD;
      thereby maximize the health benefit of warfarin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Warfarin reduces the risk of thromboembolism, but requires regular blood monitoring to keep&#xD;
      the international normalized ration (INR) within a narrow therapeutic range to achieve&#xD;
      maximum benefits. A low proportion of time spent within the therapeutic INR range, (TTR) is&#xD;
      associated with reduced warfarin efficacy and potentially harmful results. To optimize TTR,&#xD;
      international guidelines recommend the use of systematic evidence-based dosing methods&#xD;
      (anticoagulation clinic, computerized systems, manual algorithm and patient self-management).&#xD;
      A survey in the Hamilton area revealed that half of family physicians manage warfarin dosing&#xD;
      without assistance from an evidence-based method. The simple manual dosing algorithm is a&#xD;
      simple tool that helped increase the TTR at the Hamilton General Hospital's anticoagulant&#xD;
      clinic to an excellent 73% among patients with target INR range 2-3. We will test whether the&#xD;
      simple dosing algorithm can help to improve warfarin dosing of family physicians who are not&#xD;
      assisted by evidence-based methods. We will randomize family practices to either use the&#xD;
      simple dosing algorithm or to manage warfarin dosing as usual, to test whether the simple&#xD;
      dosing algorithm achieves a superior TTR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean time in therapeutic range for patients</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with TTR &gt; 65%</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between algorithm adherence and TTR</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Among patients in both baseline and study sample: proportion of patients with TTR improvement</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">553</enrollment>
  <condition>Warfarin Dosing</condition>
  <arm_group>
    <arm_group_label>Algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Care as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Algorithm</intervention_name>
    <description>Warfarin Dosing algorithm (paper and electronic version)</description>
    <arm_group_label>Algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Family practices that:&#xD;
&#xD;
               1. currently do not employ an evidence-based dosing method (anticoagulant clinic,&#xD;
                  computer system, manual algorithm or patient self-testing),&#xD;
&#xD;
               2. manage warfarin maintenance dosing in at least 10 patients with target INR 2-3,&#xD;
                  and&#xD;
&#xD;
               3. have at least one family physician providing written informed consent.&#xD;
&#xD;
          -  Patients who:&#xD;
&#xD;
               1. are on long-term warfarin treatment (&gt; 6 weeks before study entry and expected to&#xD;
                  continue for at least 6 more months) with target INR 2-3, for whom warfarin is&#xD;
                  managed by a participating family physician,&#xD;
&#xD;
               2. patient provides written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Family practices that:&#xD;
&#xD;
               1. are planning to start employing an evidence-based method for warfarin dosing&#xD;
                  within the next year,&#xD;
&#xD;
               2. are not expected to enroll at least 10 patients on long-term warfarin treatment&#xD;
                  with target INR 2-3.&#xD;
&#xD;
          -  Patients:&#xD;
&#xD;
               1. with &lt; 3 months warfarin management prior to the baseline observation,&#xD;
&#xD;
               2. patients on warfarin with a target INR other than 2-3, and&#xD;
&#xD;
               3. patients for whom warfarin is managed by a physician who is not participating in&#xD;
                  the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Connolly</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caroline Medical Group</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 4C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Stuart Connolly</name_title>
    <organization>McMaster University</organization>
  </responsible_party>
  <keyword>INR Control</keyword>
  <keyword>Warfarin dosing</keyword>
  <keyword>Family physicians</keyword>
  <keyword>Cluster randomization</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

